# Otonomy, Inc. clinical trials: 22 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials with Otonomy, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Otonomy, Inc.: 22 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/otonomy-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 2, 2021 | NCT04829214 | OTO-313 in Subjects With Unilateral Subjective Tinnitus | Otonomy, Inc. | Phase 2 | Completed | Subjective Tinnitus | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04829214) |
| October 17, 2019 | NCT04129775 | OTO-413 in Subjects With Speech-in-Noise Hearing Impairment | Otonomy, Inc. | Phase 1/2 | Completed | Sensorineural Hearing Loss | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04129775) |
| April 17, 2019 | NCT03918109 | OTO-313 in Subjects With Subjective Tinnitus | Otonomy, Inc. | Phase 1/2 | Completed | Tinnitus, Subjective | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03918109) |
| September 10, 2018 | NCT03664674 | Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease | Otonomy, Inc. | Phase 3 | Completed | Meniere Disease | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03664674) |
| December 19, 2016 | NCT02997189 | Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss | Otonomy, Inc. | Phase 2 | Terminated | Cisplatin Induced Hearing Loss | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02997189) |
| June 15, 2016 | NCT02801370 | Phase 3 Study of OTO-201 in Acute Otitis Externa | Otonomy, Inc. | Phase 3 | Completed | Acute Otitis Externa, Swimmer's Ear | 262 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02801370) |
| May 11, 2016 | NCT02768662 | A 6-Month Extension Study of OTO-104 in Meniere's Disease | Otonomy, Inc. | Phase 3 | Terminated | Meniere's Disease | 142 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02768662) |
| April 15, 2016 | NCT02740387 | Open Label Study of OTO-104 in Subjects With Meniere's Disease | Otonomy, Inc. | Phase 2 | Terminated | Meniere's Disease | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02740387) |
| March 25, 2016 | NCT02719158 | Dose Ranging Study of OTO-201 in AOMT | Otonomy, Inc. | Phase 2 | Completed | Acute Otitis Media, AOMT | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02719158) |
| March 23, 2016 | NCT02717442 | Study of OTO-104 in Subjects With Unilateral Meniere's Disease | Otonomy, Inc. | Phase 3 | Terminated | Meniere's Disease | 176 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02717442) |
| March 11, 2016 | NCT02706730 | A 6-Month Extension Study of OTO-104 in Meniere's Disease | Otonomy, Inc. | Phase 3 | Terminated | Meniere's Disease | 189 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02706730) |
| November 23, 2015 | NCT02612337 | Study of OTO-104 in Subjects With Unilateral Meniere's Disease | Otonomy, Inc. | Phase 3 | Completed | Meniere's Disease | 166 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02612337) |
| November 9, 2015 | NCT02600559 | Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes | Otonomy, Inc. | Phase 3 | Completed | Otitis Media | 501 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02600559) |
| July 30, 2015 | NCT02511561 | OTO-201 for the Treatment of Otitis Externa | Otonomy, Inc. | Phase 2 | Completed | Otitis Externa | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02511561) |
| April 3, 2015 | NCT02408796 | Open-Label Study of OTO-201 for Treatment of AOMT | Otonomy, Inc. | Phase 2 | Completed | Acute Otitis Media, AOMT | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02408796) |
| January 30, 2015 | NCT02350998 | Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration | Otonomy, Inc. | Phase 3 | Completed | Bilateral Middle Ear Effusion | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02350998) |
| October 15, 2014 | NCT02265393 | A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom | Otonomy, Inc. | Phase 2 | Completed | Meniere's Disease | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02265393) |
| September 24, 2013 | NCT01949155 | OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement | Otonomy, Inc. | Phase 3 | Completed | Otitis Media With Effusion | 266 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01949155) |
| September 24, 2013 | NCT01949142 | OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement | Otonomy, Inc. | Phase 3 | Completed | Otitis Media With Effusion | 266 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01949142) |
| December 24, 2012 | NCT01755286 | OTO-201 for Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement | Otonomy, Inc. | Phase 1 | Completed | Bilateral Middle Ear Effusion Requiring Tympanostomy Tube Placement | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01755286) |
| August 9, 2011 | NCT01412177 | OTO-104 for the Treatment of Meniere's Disease | Otonomy, Inc. | Phase 2 | Completed | Meniere's Disease | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01412177) |
| March 10, 2010 | NCT01084525 | OTO-104 for Meniere's Disease | Otonomy, Inc. | Phase 1 | Completed | Meniere's Disease | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01084525) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 2 |
| Phase 1/2 | 2 |
| Phase 2 | 8 |
| Phase 3 | 10 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 17 |
| Terminated | 5 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Meniere Disease | 9 |
| Otitis Media | 5 |
| Vertigo | 5 |
| Tinnitus | 4 |
| Hearing Loss | 3 |
| Otitis | 2 |
| Otitis Media with Effusion | 2 |
| Otitis Externa | 2 |
| Hearing Loss, Sensorineural | 1 |
| Hearing Loss, Hidden | 1 |
| Endolymphatic Hydrops | 1 |
| Labyrinth Diseases | 1 |
| Ear Diseases | 1 |
| Otorhinolaryngologic Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Tools wholesalers in the United States](https://specstream.ai/data/businesses/tools-wholesalers/united-states)
- [Importers in the United States](https://specstream.ai/data/businesses/importers/united-states)
- [B2B food products companies in the United States](https://specstream.ai/data/businesses/b2b-food-products-companies/united-states)
- [Orthodontics practices in the United States](https://specstream.ai/data/businesses/orthodontics-practices/united-states)
- [Contractors in the United States](https://specstream.ai/data/businesses/contractors/united-states)
- [Sheet metal fabricators in the United States](https://specstream.ai/data/businesses/sheet-metal-fabricators/united-states)
